Occurrence of subacute cutaneous lupus erythematosus after treatment with fluorouracil and capecitabine - 24/04/13
, Armin Gerger, MD b, Wolfgang Salmhofer, MD a, Elisabeth Aberer, MD a
Reprint requests: Birger Kränke, MD, Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, Graz, Austria.Abstract |
Capecitabine, an oral fluoropyrimidine and 5-fluorouracil (FU) prodrug recently approved for the treatment of metastatic colon and breast cancer, is currently under investigation in patients with gastric cancer. It has the advantage of oral administration, and good tolerability with its activity being comparable with intravenous 5-FU. Lupus erythematosus and lupuslike drug eruptions have been observed after 5-FU treatment, but so far no cases of subacute cutaneous lupus erythematosus have been described in patients treated either with capecitabine or 5-FU. We report a patient who developed subacute cutaneous lupus erythematosus after administration of 5-FU and capecitabine.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 59 - N° 2S
P. S4-S6 - août 2008 Retour au numéro
Article précédent
- Metastatic basal cell carcinoma presenting with unilateral upper extremity edema and lymphatic spread
- A. David Soleymani, Noah Scheinfeld, Katherine Vasil, Mark A. Bechtel
- Treatment of extra-abdominal aggressive fibromatosis with pegylated interferon
- Gabriele Stengel, Dieter Metze, Bernd Dörflinger, Thomas A. Luger, Markus Böhm
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?